Quest Diagnostics Incorporated (DGX) fair value: what the stock is really worth
As of Nov 4, 2026: fair value (intrinsic value) of Quest Diagnostics Incorporated stock $172, price $256, that is 32.8% below the price, quality 66 out of 100. Rating: overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $112.13 – $255.68 · fair‑value band $106.30 – $247.16 · the $255.68 price screens above the $171.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Quest Diagnostics in your weekly email
Every Wednesday you see whether Quest Diagnostics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Show moreShow less
It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals.
In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services.
Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions.
Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Stock analysis
Quest Diagnostics Incorporated (DGX) currently trades at $255.68, while our model-based Fair Value estimate is $171.87, 33% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $188.02 per share, and 0 of the 23 models we run sit above the $255.68 price.
Bear case: the Dividend Discount group reads lowest at $48.85, and 23 of the 23 models stay below the price. Data coverage for this calculation is high.
Scenario range: $106.30 (bear) to $247.16 (bull), the price of $255.68 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Quest Diagnostics Incorporated reported revenue of $11.0B in FY2025 versus $10.8B in FY2021, a compound +0.6%/yr. Reported net income was $992M in FY2025, compounding −16.0%/yr from FY2021.
Key figures
Market cap $28.6B Large · P/E ratio 25.4 · P/S ratio 2.42 · EPS (TTM) $10.08 · Dividend yield 1.3% · Net margin 9.5% · Return on equity 15.3% · Return on assets (EBIT) 11.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 61 out of 100 (medium confidence).
What moves the price
The share trades at its 52-week high and 50% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −33%, DGX screens richer than that median.
Fair Value models
Bear$106.30Fair Value $171.87Bull$247.16
Price $255.68 · Downside -32.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($5.69 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 5 officers or directors sold shares worth $12.2M and none bought.
SaleGary M PfeifferDirector1,203 shares at $243.00$292,329Oct 26, 202610b5-1 plan
SaleJ. E. DavisCEO and President, Director4× since Nov 25, 2025: 85,093 shares, avg. $200.76$17.1MSep 1, 202610b5-1 plan
SaleMichael E PrevoznikSVP & General Counsel4× since Feb 19, 2026: 28,192 shares, avg. $235.87$6.6MAug 28, 202610b5-1 plan
SaleMark E DelaneySVP & Chief Commercial Officer2× since Nov 18, 2025: 9,546 shares, avg. $195.37$1.9MJul 28, 202610b5-1 plan
SaleKarthik KuppusamySVP, Clinical Solutions2× since Mar 4, 2026: 10,775 shares, avg. $201.19$2.2MJun 4, 2026
SalePatrick PlewmanSVP for Diagnostic Services4× since Feb 10, 2026: 9,885 shares, avg. $204.87$2.0MMar 5, 202610b5-1 plan
SaleCatherine T. DohertyEVP, Regional Businesses4× since Feb 13, 2026: 33,788 shares, avg. $206.13$7.0MMar 5, 202610b5-1 plan
SaleVicky B GreggDirector1,250 shares at $191.76$239,700Nov 25, 2025
Plus 28 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.69/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+11.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
Start year 2020 (pandemic). Over 10 years: +3.9% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−2.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.6%
Dividend (yield on the price)1.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−3.6% vs 6.8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 15%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+9.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +6.8% a year for the price and +2.6% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Moderate moat from scale in diagnostics network is the main strength while limited signals on innovation ownership, human capital and insider alignment form the key weakness.
Main risk: Proposed PAMA rate cuts by CMS could reduce payments for hundreds of lab tests and pressure margins on services reimbursed by Medicare and Medicaid.
Bull case: Quest could leverage its scale, automation and AI tools to offset reimbursement pressure through efficiency gains and expanded advanced testing partnerships with health systems.
Bear case: If Medicare cuts materialise without reform and consumer platforms erode volumes, Quest might face sustained margin compression and slower growth in its core testing business.
Quest Diagnostics is shifting a long-time executive to oversee its health systems partnerships and a multi-year modernization of order-to-cash processes. This internal push coincides with expanded advanced testing in areas like oncology while Medicare reimbursement pressures remain a recurring concern for the lab sector. Will the efficiency gains from these operational changes prove sufficient to support sustained performance?
Compare Quest Diagnostics Incorporated with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score66 · Above median
Fair Value upside−32.8% · Above median
Profitability
Return on equity (12 months)15.3% · Top 25%
Return on assets6.1% · Top 25%
Net margin (12 months)9.5% · Above median
Operating margin (12 months)15.6% · Above median
Growth and dividend
Revenue growth (quarter YoY)10.0% · Above median
Dividend yield (12 months)1.3% · Below median
Balance sheet
Debt / equity0.72× · Highest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (12 months)25.4× · Cheaper than median
P/B3.99× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)2.42× · Cheaper than median
Price / free cash flow21.1× · Cheaper than median
EV/EBITDA14.2× · Cheaper than median
PEG1.58× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)50· sector 38
PAST (return on equity)61· sector 15
HEALTH (low debt)64· sector 95
DIVIDEND (yield)26· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Quest Diagnostics Incorporated (DGX) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $171.87 versus a price of $255.68, about 33% lower (overvalued).
What is the fair value of DGX?
Our model-based fair value for Quest Diagnostics Incorporated is $171.87 (as of Nov 6, 2026), built from audited fundamentals. The current price: $255.68.
What is the quality score of DGX?
Quest Diagnostics Incorporated has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Quest Diagnostics Incorporated (DGX)?
Our model-based price target is the fair value of $171.87 (as of Nov 6, 2026) from 23 valuation models. Cautious scenario $106.30, optimistic scenario $247.16. It is a calculation from audited fundamentals, not an analyst target.
What is the Quest Diagnostics Incorporated stock forecast for 2026?
Our models put fair value at $171.87, about 33% lower versus a price of $255.68 (overvalued). Cautious scenario $106.30, optimistic scenario $247.16. The calculation is refreshed regularly with new filings.
What is the revenue of Quest Diagnostics Incorporated (DGX)?
Quest Diagnostics Incorporated reported trailing-twelve-month revenue of about $11.8B (latest available figure, as of Nov 6, 2026).
Does Quest Diagnostics Incorporated pay a dividend?
Quest Diagnostics Incorporated currently shows a dividend yield of 1.32% relative to its recent price (as of Nov 6, 2026).
What growth is priced into Quest Diagnostics Incorporated (DGX)?
For today's price to be fair in a discounted-cash-flow model, Quest Diagnostics Incorporated would have to grow free cash flow by +9.3 % per year for five years (discount rate 8.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.2 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of DGX use?
Our models discount Quest Diagnostics Incorporated at 8.2 %: a base by market capitalisation (large), damped by beta 0.54, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Quest Diagnostics Incorporated that is +9.3 % per year a year over ten years, using the same discount rate (8.2 %) and the same formula as our fair value.
How much growth has Quest Diagnostics Incorporated (DGX) delivered so far?
Over the past 5 years revenue at Quest Diagnostics Incorporated grew +3.2 % a year. The price currently implies +9.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Quest Diagnostics Incorporated (DGX) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Quest Diagnostics Incorporated (+9.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Quest Diagnostics Incorporated (DGX)?
The free-cash-flow yield on the price is 4.75 %: that much free cash flow Quest Diagnostics Incorporated produces per unit of market value. When it exceeds the discount rate of our models (8.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Quest Diagnostics Incorporated (DGX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Quest Diagnostics Incorporated it is $171.87 per share (as of Nov 6, 2026), against a price of $255.68. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Quest Diagnostics Incorporated stock overvalued or undervalued in 2026?
As of Nov 6, 2026, DGX trades above its calculated fair value: price $255.68, fair value $171.87, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DGX?
No. The price is what the market pays today ($255.68); the fair value is what the company's own numbers justify ($171.87). For Quest Diagnostics Incorporated the two are $83.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is Quest Diagnostics Incorporated worth?
The market values Quest Diagnostics Incorporated at about $28.6B (market capitalisation, as of Nov 6, 2026). Per share that is $255.68; our models calculate a fair value of $171.87 per share.
What do the bullish and bearish scenarios say about DGX?
Our models span a range for Quest Diagnostics Incorporated: cautious scenario $106.30, base $171.87, optimistic $247.16 per share (as of Nov 6, 2026, price $255.68). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DGX?
Quest Diagnostics Incorporated trades at a price-to-earnings ratio of 25.4 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $171.87 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 27.6 (reported for FY2025: 29.1). Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), earnings ex one-offs: 17.5. Other multiples: PEG 1.6, P/B 4.0, P/S 2.4, EV/EBITDA 14.2.
What is the PEG ratio of DGX?
The PEG ratio of Quest Diagnostics Incorporated is 1.58 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Quest Diagnostics Incorporated (DGX)?
Balance-sheet figures for Quest Diagnostics Incorporated (as of Nov 6, 2026): return on equity 15.3%, debt of 0.72 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is DGX from its 52-week high?
Quest Diagnostics Incorporated trades at $255.68, at its 52-week high of $255.68 and 50% above the low of $170.62 (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of $171.87 is for.
Which stocks are comparable to Quest Diagnostics Incorporated?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Quest Diagnostics Incorporated stock attractive at the current price?
The data as of Nov 6, 2026: price $255.68, calculated fair value $171.87 (−33%), Quality Score 66/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DGX calculated?
We run Quest Diagnostics Incorporated through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $171.87, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6% above its aggregate fair value. Quest Diagnostics Incorporated itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Quest Diagnostics Incorporated (DGX)?
The closing price on Nov 4, 2026 was $255.68. Our model-based fair value is $171.87, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Quest Diagnostics Incorporated right now?
The price sits above even our optimistic bull case ($247.16). The favourable scenario is already priced in. Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($106.30 to $247.16) leaves room in how you read the outcome.
Where does the earnings growth of Quest Diagnostics Incorporated (DGX) come from?
Earnings per share at Quest Diagnostics Incorporated grew +6.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.2 %, EBIT margin −1.7 %, tax rate +3.7 %, residual (interest, one-offs) −1.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Quest Diagnostics Incorporated
How large is the market capitalisation of Quest Diagnostics Incorporated (DGX)?
The market capitalisation of Quest Diagnostics Incorporated is $28.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Quest Diagnostics Incorporated (DGX)?
The price-to-sales ratio of Quest Diagnostics Incorporated is 2.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Quest Diagnostics Incorporated (DGX)?
Earnings per share at Quest Diagnostics Incorporated are $10.08 (price ÷ EPS = P/E 25.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Quest Diagnostics Incorporated (DGX)?
The dividend yield of Quest Diagnostics Incorporated is 1.3% (payout 31.8%, on adjusted earnings, reported 33.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Quest Diagnostics Incorporated (DGX)?
The net margin of Quest Diagnostics Incorporated is 9.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Quest Diagnostics Incorporated (DGX)?
The return on equity (ROE) of Quest Diagnostics Incorporated is 15.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Quest Diagnostics Incorporated (DGX)?
On an EBIT basis the return on assets of Quest Diagnostics Incorporated is 11.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Quest Diagnostics Incorporated (DGX)?
The operating margin of Quest Diagnostics Incorporated is 15.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Quest Diagnostics Incorporated (DGX)?
Revenue at Quest Diagnostics Incorporated is growing +10.0% versus a year earlier (3y avg +3.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Quest Diagnostics Incorporated (DGX)?
Earnings per share at Quest Diagnostics Incorporated are growing +28.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Quest Diagnostics Incorporated (DGX) carry?
The net debt of Quest Diagnostics Incorporated is $6.5B (fiscal year 2025, ≈ 4.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Quest Diagnostics Incorporated in the live analysis
One click puts Quest Diagnostics Incorporated on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026